Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Regeneron Pharmaceuticals Inc. closed 45.10% below its 52-week high of $1,211.20, which the company reached on August 27th.
Jim Cramer Wants You to ‘Own’ Regeneron Pharmaceuticals (REGN) Shares
We recently published a list of Jim Cramer’s Latest Stock Moves: Top 10 Calls. In this article, we are going to take a look ...
BioSpace3d
Regeneron Loses Appeal to Block Amgen’s Eylea Biosimilar
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires
We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands ...
THE 2025 DERMATOLOGY FOUNDATION-SKIN OF COLOR SOCIETY COLLABORATIVE MID-CAREER AWARD SPONSORED BY SANOFI AND REGENERON IS BESTOWED O…
The Dermatology Foundation (DF) and the Skin of Color Society (SOCS) announce that Crystal U. Aguh, MD, FAAD, is the 2025 ...
Regeneron Pharmaceuticals (NasdaqGS:REGN) Shares Dip 1% Despite Positive Dupixent Trial Results
Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...
Regeneron finalists from Long Island in Washington, D.C., for a shot at up to $250,000 in prize money
Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...
Regeneron down 3% after appeals court decision in Amgen patent fight
EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...
Seeking Alpha6d
REGN Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...
FINAL REGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Regeneron Therapeutics, Inc. Investors to Join the Class Action Lawsuit
NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...